Literature DB >> 4416322

The influence of total gastrectomy on survival in malignant Zollinger-Ellison tumors.

P S Fox, J W Hofmann, J J Decosse, S D Wilson.   

Abstract

The effect of total gastrectomy on the biologic behavior of malignant gastrinomas was studied from patient data collected in the ZE tumor registry. A total of 267 patients with documented metastatic tumor had definitive gastric operations. In the 137 patients who had total gastrectomy, survival was 75% at one year, 55% at five years and 42% at ten years. In the 130 patients who had lesser gastric operations, survival was 51% at one year, 27% at five years and 18% at ten years. Deaths from progressive tumor growth occurred in 17% of the patients at risk after total gastrectomy and 30% of the patients at risk after lesser gastric operations. A subgroup of 127 patients with documented liver metastasis had definitive gastric operations. Seventythree patients with liver metastasis had total gastrectomy with survival of 68% at one year, 42% at five years and 30% at ten years. Fifty-four patients with liver metastasis had lesser gastric operations with survival of 44% at one year, 7% at five years and none at ten years. Deaths from progressive tumor growth occurred in 25% of the patients at risk after total gastrectomy and 50% of the patients at risk after lesser gastric operations. Regression of metastatic ZE tumor was clearly documented in only four patients; all had total gastrectomy. Presumptive regression of primary tumor occurred in seven patients, five had total gastrectomy. The study clearly demonstrated that total gastrectomy was the procedure of choice for malignant ZE tumors, even in the presence of widespread metastasis. The results provided indirect evidence to support a gastric feedback effect which influences growth of gastrinomas; however, the results also show that total gastrectomy furnished neither predictable nor permanent protection from subsequent tumor growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4416322      PMCID: PMC1344141          DOI: 10.1097/00000658-197410000-00020

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  14 in total

1.  THE ZOLLINGER-ELLISON SYNDROME: RE-APPRAISAL AND EVALUATION OF 260 REGISTERED CASES.

Authors:  E H ELLISON; S D WILSON
Journal:  Ann Surg       Date:  1964-09       Impact factor: 12.969

2.  SPONTANEOUS REMISSION OF ZOLLINGER-ELLISON SYNDROME.

Authors:  C S MELNYK; W W KRIPPAEHNE; J A BENSON; J E DUNPHY
Journal:  Arch Intern Med       Date:  1965-01

3.  Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas.

Authors:  R M ZOLLINGER; E H ELLISON
Journal:  Ann Surg       Date:  1955-10       Impact factor: 12.969

Review 4.  Surgical management of the Zollinger-Ellison syndrome.

Authors:  P S Fox; J W Hofmann; S D Wilson; J J DeCosse
Journal:  Surg Clin North Am       Date:  1974-04       Impact factor: 2.741

5.  Clinical role of serum gastrin measurements in the Zollinger-Ellison syndrome.

Authors:  J C Thompson; D D Reeder; H H Bunchman
Journal:  Am J Surg       Date:  1972-08       Impact factor: 2.565

6.  Proceedings: Malignant gastrinoma following total gastrectomy.

Authors:  E Passaro; H E Gordon
Journal:  Arch Surg       Date:  1974-04

7.  Ulcerogenic tumor, a case report.

Authors:  R S Smalley; H Wilde
Journal:  Alaska Med       Date:  1968-03

8.  New studies in the Zollinger-Ellison syndrome.

Authors:  E Passaro; N Basso; R E Sanchez; H E Gordon
Journal:  Am J Surg       Date:  1970-08       Impact factor: 2.565

9.  Longevity studies following total gastrectomy. In children with the Zollinger-Ellison syndrome.

Authors:  S D Wilson; W J Schulte; R C Meade
Journal:  Arch Surg       Date:  1971-08

10.  Zollinger-Ellison syndrome. Clinical features and long-term follow-up.

Authors:  A J Cameron; H N Hoffman
Journal:  Mayo Clin Proc       Date:  1974-01       Impact factor: 7.616

View more
  21 in total

Review 1.  Unresolved surgical issues in the management of patients with Zollinger-Ellison syndrome.

Authors:  J A Norton; R T Jensen
Journal:  World J Surg       Date:  1991 Jan-Feb       Impact factor: 3.352

2.  Medical staff conference: pancreatic diarrheal syndromes.

Authors:  L H Smith; H Klaeveman
Journal:  West J Med       Date:  1975-10

3.  Ectopic apudocarcinomas and associated endocrine hyperplasias of the foregut.

Authors:  S R Friesen; J E McGuigan
Journal:  Ann Surg       Date:  1975-10       Impact factor: 12.969

4.  Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

Authors:  S M Wood; M E Kraenzlin; T E Adrian; S R Bloom
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

5.  The role of surgery in patients with Zollinger-Ellison syndrome (ZES) managed medically.

Authors:  M F Brennan; R T Jensen; R A Wesley; J L Doppman; D M McCarthy
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

Review 6.  Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I.

Authors:  M Pipeleers-Marichal; C Donow; P U Heitz; G Klöppel
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

7.  Zollinger-Ellison syndrome. Spontaneous regression of advanced intra-abdominal metastases with 20 year survival.

Authors:  C E Davis; J H Vansant
Journal:  Ann Surg       Date:  1979-05       Impact factor: 12.969

8.  Forty-year appraisal of gastrinoma. Back to the future.

Authors:  E C Ellison
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

9.  The role of surgery in the Zollinger-Ellison syndrome.

Authors:  J C Thompson; B G Lewis; I Wiener; C M Townsend
Journal:  Ann Surg       Date:  1983-05       Impact factor: 12.969

10.  Comparison of four provocative tests for the diagnosis of gastrinoma.

Authors:  M E Romanus; J A Neal; W G Dilley; G S Leight; W M Linehan; R J Santen; J R Farndon; R S Jones; S A Wells
Journal:  Ann Surg       Date:  1983-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.